RCS - Kanabo Group PLC - Partnership with BRITISH CANNABIS™

KanaboAnnouncement

02/11/2023 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231102:nRSB1152Sa&default-theme=true

RNS Number : 1152S  Kanabo Group PLC  02 November 2023

 

2 November 2023

 

Kanabo Group Plc

("Kanabo", the "Group" or the "Company")

 

Partnership with BRITISH CANNABIS™

 

Kanabo Group plc (LSE: KNB), the patient-focused provider of digital health
services and specialist medicines, including medicinal cannabis, is pleased to
announce that it has entered into a partnership with BRITISH CANNABIS™ to
supply the CBD by BRITISH CANNABIS™ range of pharmacy-grade CBD health
supplements to patients via a prescription service through the Group's online
pain management clinic, Treat It (https://treat-it.clinic/) .

 

The partnership will allow doctors to prescribe the CBD by BRITISH CANNABIS™
products to patients via the Treat It platform. Focused on secondary care,
Treat It enables patients access to healthcare professionals via its secure,
digital healthcare platform. These medical professionals deliver a full
diagnosis as part of a personalised patient care plan and are able to offer
treatments, including the prescription of medicinal cannabis, for individuals
seeking relief from chronic pain. By incorporating CBD by BRITISH CANNABIS™
products into our offerings, Kanabo continues to increase the accessibility
and affordability of high quality, alternative pain management solutions to
improve overall patient quality of life.

 

From November, Treat It will also be included in Canndr, an online medicinal
cannabis app from BRITISH CANNABIS™ which enables patients to select and
review quality cannabis medicines on the market, gain consultancy advice and
select from a number of suitable prescribing clinics.

 

Avihu Tamir, Chief Executive Officer of Kanabo, commented:

 

"At Kanabo, we aim to increase medicinal cannabis access for more patients.
This partnership allows Treat It doctors to include a wider range of quality
CBD supplements in our telemedicine offerings. We're eager to further enhance
patient-centric healthcare and treatment options. This partnership is just the
beginning, and we hope to announce more expansive collaborations in due
course."

 

Steve Batchelor, BRITISH CANNABIS™ Marketing Director commented:

 

"We are thrilled to join forces with Treat It to make CBD products from our
long-standing pharmacy retail brand accessible to pain patients through
prescriptions. This partnership represents a significant step forward in
expanding patient choices and empowering doctors to explore naturally-derived
supplements, as alternatives to traditional pharmaceutical care paths.

 

"We are also pleased that thousands of long-term CBD customers will have the
option to consult with Treat It's network of specialist pain doctors,
assessing their own particular needs and determining things like what delivery
formats, when and how much CBD they could be taking."

 

Enquiries:

 Kanabo Group plc                                                 via Vigo Consulting

 Avihu Tamir, Chief Executive Officer                             +44 (0)20 7390 0230

 Assaf Vardimon, Chief Financial Officer

 Ian Mattioli, Non-Executive Chair of the Board

 Peterhouse Capital Ltd (Financial Adviser)                       +44 (0)20 7469 0930

 Eran Zucker / Lucy Williams / Charles Goodfellow
 Vigo Consulting (Financial Public Relations/Investor Relations)   +44 (0)20 7390 0230

 Jeremy Garcia / Fiona Hetherington / Verity Snow

 kanabo@vigoconsulting.com (mailto:kanabo@vigoconsulting.com)

 

About BRITISH CANNABIS™

 

BRITISH CANNABIS™ are pioneers in the UK cannabis industry since 2015,
specialising in high-quality CBD products trusted by pharmacists and over
40,000 consumers alike. With over six years of experience and a strong
reputation, BRITISH CANNABIS™ is dedicated to providing natural wellness
solutions and promoting education surrounding CBD.

 

About Kanabo Group plc

 

Kanabo Group plc (LSE:KNB) is a digital health company committed to
transforming patient care through its innovative technology platform and
specialised treatment offerings. Since its inception in 2017, Kanabo has been
focused on researching, developing, and commercialising regulated medicinal
cannabis-derived formulations and therapeutic inhalation devices.

 

Kanabo's NHS-approved online telehealth platform, The GP Service, provides
patients with video consultations, online prescriptions, and primary care
services. Leveraging its telehealth capabilities, in February 2023, Kanabo
launched Treat It - an online clinic focused on chronic pain management
providing patients with secondary care.

 

With its two complementary business divisions, Kanabo has established itself
as an end-to-end digital health provider, offering telehealth consultations,
prescriptions, alongside the delivery of tailored treatments.

 

The Company's partially owned subsidiary, Kanabo Agritec Ltd, is a cultivation
consultancy supporting cannabis businesses in developing new farms through
infrastructural, research, and product guidance. These farms deliver
high-quality raw materials for Kanabo's formulas and product line.

 

At Kanabo Group Plc, we are dedicated to providing patients with the highest
quality medical treatments and more accessible healthcare experiences.

 

Visit (http://www.kanabogroup.com/) www.kanabogroup.com
(http://www.kanabogroup.com/) for more information.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABBBMTMTTMTRJ